Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

A0325450

Alfacalcidol

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

1α-Hydroxy-vitamin D3, 1α-Hydroxy-cholecalciferol, Alfacalcidol

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C27H44O2
CAS-Nummer:
41294-56-8
Molekulargewicht:
400.64
MDL-Nummer:
MFCD00868328
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329770599
NACRES:
NA.24

Biologische Quelle

synthetic

Qualität

pharmaceutical primary standard

Agentur

EP

API-Familie

alfacalcidol

Form

solid

Hersteller/Markenname

EDQM

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

−20°C

SMILES String

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C

InChI

1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1

InChIKey

OFHCOWSQAMBJIW-AVJTYSNKSA-N

Angaben zum Gen

human ... VDR(7421)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the authority of the issuing pharmacopoeia. For further information and support please go to the website of the issuing pharmacopoeia.

Alfacalcidol is an active metabolite of vitamin D, used as a vitamin supplement due to it longer half-life. It is found to be effective in regulating calcium balance/bone metabolism.

Anwendung

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Synthetisches Vitamin D3-Aanalogon, das zu 1,25-Dihydroxycholecalciferol verstoffwechselt wird. Hemmt die Knochenresorption und stimuliert die Knochenbildung. Unterdrückt Parathormon-Sekretion durch Rindemebenschilddrüsenzellen.

Verpackung

Dieses Produkt wird, wie von der entsprechenden Pharmakopöe geliefert, angeboten. Die aktuellen Mengeneinheiten finden Sie im Referenzsubstanzen-Katalog der EDQM.

Sonstige Hinweise

Kann Verkaufsbeschränkungen unterliegen.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Piktogramme

Skull and crossbones
GHS06

Signalwort

Danger

H-Sätze

H300

Gefahreneinstufungen

Acute Tox. 1 Oral

Lagerklassenschlüssel

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Florent Richy et al.
Aging clinical and experimental research, 17(2), 133-142 (2005-06-28)
Alfacalcidol (1-alpha-hydroxyvitamin D3) is a non-endogenous analog of vitamin D which can bypass the renal and intestinal regulatory mechanisms that control the production of calcitriol (1,25-hydroxyvitamin D3, the active form of vitamin D, D-Hormone). Alfacalcidol may be metabolized into calcitriol
R M Francis
Calcified tissue international, 60(1), 111-114 (1997-01-01)
: There is a decline in serum 25 hydroxyvitamin D (25OHD), 1,25 dihydroxyvitamin D (1,25(OH)2D), and calcium absorption with advancing age, which may lead to secondary hyperparathyroidism and bone loss. Studies show a relationship between serum 25OHD and bone density
J D Ringe et al.
Rheumatology international, 28(2), 103-111 (2007-08-02)
While in other chronic diseases combined treatment regimens are the rule there is a lack of reported experience or study data on combining different specific drugs to treat osteoporosis. Significant differences in the mode of action (MOA) of the substances
P Sambrook
Calcified tissue international, 65(4), 341-343 (1999-09-15)
There is increasing evidence that D-hormones (active vitamin D metabolites) are effective agents in preventing posttransplantation bone loss of various organs. This effect may relate to several mechanisms including reversal of secondary hyperparathyroidism from cyclosporine, reversal of corticosteroid effects on
Novel approach for the determination of alfacalcidol in bulk and tablet dosage form using spectrophotometric method
Saeed-Ul-Hassan S, et al.
Latin American Journal of Pharmacy, 32(5), 784-788 (2013)
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.